Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer.
Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer.
复制标题
DOI：
10.1158/1078-0432.ccr-20-4116
复制
发表时间：
2022-02-15
期刊：
影响因子：
--
通讯作者：
Hidalgo M
中科院分区：
文献类型：
--
作者：
Grossman JE;Muthuswamy L;Huang L;Akshinthala D;Perea S;Gonzalez RS;Tsai LL;Cohen J;Bockorny B;Bullock AJ;Schlechter B;Peters MLB;Conahan C;Narasimhan S;Lim C;Davis RB;Besaw R;Sawhney MS;Pleskow D;Berzin TM;Smith M;Kent TS;Callery M;Muthuswamy SK;Hidalgo M
胰腺导管腺癌（PDAC）仍然是一个重要的健康问题。对于大多数患者来说，没有靶向治疗的选择，现有的治疗方法受到毒性的限制。HOPE试验（利用类器官进行个性化治疗）是一项试点可行性试验，旨在前瞻性地从PDAC患者中产生患者源性类器官（PDO），并测试其药物敏感性及其与临床结局的相关性。PDO是从包括基础和经典PDAC亚型的PDAC患者的异质性人群中建立的。开发了一种将PDO分类为对化疗方案敏感或耐药的方法，以预测患者的临床结局。PDO的药物敏感性试验与个体患者的临床治疗反应相关。这些数据支持对PDO的研究，以指导PDAC前瞻性干预性试验中的治疗。
Pancreatic ductal adenocarcinoma (PDAC) remains a significant health issue. For most patients, there are no options for targeted therapy, and existing treatments are limited by toxicity. The HOPE trial (Harnessing Organoids for Personalized Therapy) was a pilot feasibility trial aiming to prospectively generate patient-derived organoids (PDO) from patients with PDAC and test their drug sensitivity and correlation with clinical outcomes. PDOs were established from a heterogeneous population of patients with PDAC including both basal and classical PDAC subtypes. A method for classifying PDOs as sensitive or resistant to chemotherapy regimens was developed to predict the clinical outcome of patients. Drug sensitivity testing on PDOs correlated with clinical responses to treatment in individual patients. These data support the investigation of PDOs to guide treatment in prospective interventional trials in PDAC.